Update shared on24 Oct 2025
Fair value Increased 0.36%Analysts have modestly raised their price target for MetLife, increasing it from $93.00 to $93.33 per share. They cited slight improvements in projected revenue growth and profit margins as the reason for the adjustment.
What's in the News
- MetLife and Empathy announced Leave Support, a digital platform to assist employees with the challenges of taking a leave of absence, including planning, routine building, and return-to-work support. The platform will be available exclusively through MetLife later this year and is supported by a dedicated Care Team (Key Developments).
- MetLife introduced a new Cancer Support benefit through a partnership with Private Health Management, expanding its Critical Illness Insurance to offer personalized advice, expert-led case management, and access to top oncology specialists for employees facing cancer diagnoses (Key Developments).
- The company will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, at $1,000 per share. Redemption and regular dividend payment are scheduled for September 15, 2025 (Key Developments).
- Between April and July 2025, MetLife repurchased over 9.2 million shares for a combined total of more than $721 million as part of ongoing buyback programs (Key Developments).
Valuation Changes
- The consensus analyst price target has increased slightly from $93.00 to $93.33 per share.
- The discount rate has risen marginally, moving from 7.69% to 7.72%.
- Revenue growth forecasts have improved, increasing from 4.72% to 4.74%.
- Net profit margin projections are up slightly, going from 7.54% to 7.55%.
- The future P/E ratio has increased slightly from 10.83x to 10.85x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.